Business
Diaceutics Launches Enhanced Rare-Disease Offering
Diaceutics Launches Enhanced Rare-Disease Offering.
About this update from Diaceutics Plc
[{"type":"text","content":"\n\nDiaceutics Launches Enhanced Rare-Disease Offering\n \nSignificant expansion of lab network will deliver more rare-disease data\n \nNew contract signed to support the commercialisation of a rare-disease therapy\n \nBelfast and London, 27 August 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce a significant enhancement to its offering which has facilitated a new rare-disease contract win. Access to this new data will revolutionise the early identification of patients, a crucial growth area for pharma companies developing therapies for rare-diseases. Leveraging cutting-edge data utilisation, it will improve earlier patient diagnosis and ultimately, clinical outcomes. \n \nDriving this enhancement are 3 key developments within the Diaceutics business as follows:\n \n\n\n\n\n1. \n\n\nOnboarding of New Data Partners: A number of new rare-disease genomic lab data partners have joined the DXRX network. These partners specialise in genetic testing, including the largest recognised testing lab in the United States for genetically acquired rare diseases.\n\n\n\n\n\n\n\n\n\n\n\n\n2. \n\n\nAdvanced Lab Labelling Natural Language Processing (NLP): Diaceutics has updated its advanced lab labelling NLP process to standardise and add value to the new data. This process enables complex labelling such as pathogenic vs Variants of Unknown Significance (VUS) variant calling which until now has proven challenging for the industry to identify.\n\n\n\n\n\n\n\n\n\n\n\n\n3. \n\n\nAccess to Additional Industry Experts: The company now has a team of industry experts with deep rare-disease experience to support biopharma business opportunities and ensure clients derive maximum value from Diaceutics' deep-data offering.\n\n\n\n\n \nJordan Clark, Chief Data Officer of Diaceutics commented: \"These enhancements to our rare-disease data offering represent significant progress in our mission to support the earlier identification and treatment of patients with rare diseases. By integrating new data, advanced labelling and a specialised team, we are well-positioned to address the critical needs of this underserved market and help patients in need.\"\n \nSusanne Munksted, Chief Prec...